Hikma Pharmaceuticals Plc
HIK:LN
Latest Coverage
Overview
Company Profile
Hikma is an international pharmaceutical company conducting operations through three businesses: generic pharmaceuticals, branded pharmaceuticals and injectable pharmaceuticals. The company sells 113 branded and non-branded generic pharmaceutical products in 34 countries worldwide. The majority of Hikma's operations are in the United States, the Middle East and North Africa Region and Europe.
Classification
Sector Healthcare
Industry Pharmaceuticals
Subindustry Pharmaceutical Manufacturers - Specialty & Generic
Financials
News & Media
Latest Coverage
Corporate
Board of Directors
Said Darwazah
Chairman and Chief executive officer
Said has been appointed as Chairman of the Board of Directors in May 2014, in addition to his post as Chief Executive Officer. Said was appointed Chief Executive Officer in July 2007. Said was Chairman and Chief Executive of the Hikma’s group holding company from 1994 to 2003 and Minister of Health for the Hashemite Kingdom of Jordan from 2003 to 2006. During his thirty two years at Hikma, Said has undertaken several executive roles which have provided him with extensive experience in each functional area of Hikma’s global generic pharmaceuticals business and in the broader strategic leadership of an international entrepreneurial organisation. Said has played a key role in the development of the group strategy, including the acquisition of West-Ward Pharmaceuticals in the USA and the development of the Injectables business in Europe and the MENA region. Under Said’s leadership, Hikma’s facilities in the USA, Jordan and Portugal received US FDA approval, the leading international pharmaceutical regulatory standard. Said has a degree in industrial engineering from Purdue University and an MBA from INSEAD.
Mazen Darwazah
Executive Vice Chairman, President and CEO of MENA and Emerging Markets
Mazen was appointed President and CEO of MENA and Emerging Markets in April 2014. Mazen was appointed group Executive Vice-Chairman and MENA CEO in 2005. During his 28 years’ service at Hikma, he has held an extensive range of positions within the Group starting as a medical representative and working in different capacities including Chairman and CEO of Hikma Pharmaceuticals Limited, a major group operational and holding company. As Chief Executive of MENA, Mazen is leading the geographical expansion and consolidation of Hikma in MENA region and the formation of strategic business partnerships. Mazen is the executive lead of Hikma’s corporate social responsibility and business integrity programs. Mazen holds a BA in Business Administration from the Lebanese American University and an AMP from INSEAD. He has served as the President of the Jordanian Association of Manufacturers of Pharmaceuticals and Medical Appliances.
Robert Pickering
Senior Independent Director
Robert spent 23 years at Cazenove & Co., becoming the first Chief Executive of Cazenove Group PLC in 2001. He subsequently served as Chief Executive of JP Morgan Cazenove, until his retirement in 2008. He has extensive experience of capital raising, mergers and acquisitions and of the relationship between quoted companies and investors. Robert is a qualified solicitor with a law degree from Lincoln College, Oxford.
Ali Al-Husry
Non-executive director
Ali joined Hikma as director of Hikma Pharma Limited in 1981 and has held various directorships within the Group. Ali brings great financial experience to the Board as well as an in-depth knowledge of the MENA region and Hikma Pharmaceuticals. Ali was a founder of The Capital Bank of Jordan, which offers commercial and investment banking services, and served as Chief Executive Officer of the Bank until 2007. Ali has a degree in Mechanical Engineering from the University of Southern California and an MBA from INSEAD.
Michael Ashton
Independent non-executive director
Michael has over 30 years’ experience in the pharmaceutical industry, holding senior executive positions with Pfizer and Merck. Michael was Chief Executive Officer of SkyePharma PLC from November 1998 to March 2006 and prior to that was Chairman, President and Chief Executive Officer of Faulding. He has held a number of non-executive and advisory positions across the pharmaceutical industry. Michael has a Bachelor of Pharmacy degree from Sydney University, and his MBA degree from Rutgers University, New Jersey.
Breffni Byrne
Independent non-executive director
Breffni is a chartered accountant with over 30 years of experience in public practice, including significant international responsibilities. Breffni served as the Managing Partner of the Audit and Business Advisory practice of Arthur Andersen in Ireland and as Director of Risk Management of Andersen\'s audit practice in Middle East, India, Africa and the Nordic countries. Breffni has extensive experience in financial reporting, international operations, corporate governance and general financial and commercial matters. He is a former non-executive director of Irish Life and Permanent plc. He is considered by the Board to have recent and relevant financial experience. Breffni holds a Masters degree in Economic Science from the University College, Dublin and is a Chartered Accountant
Ronald Goode
Independent non-executive director
Ron has spent over 30 years in the international pharmaceutical industry, including roles as President of International Operations at Searle and Vice President of Clinical and Scientific Affairs at Pfizer. His extensive experience includes leading companies as CEO and acting as an adviser to companies in the pharmaceutical industry. He also advises companies involved in nanotechnology and in the information technology business sectors. Ron was formerly President and Chief Executive Officer of Unimed Pharmaceuticals, Inc. and eXegenics Inc. He is a trustee of Thunderbird School of Global Management, which is ranked by the Financial Times as the premier international business school. Ron has a PhD from the University of Georgia and a MS and BS from the University of Memphis.
Patrick Butler
Independent non-executive director
Pat is a former Senior Director at Mckinsey & Co. During his 25 years at McKinsey, he focused on advising large corporations in the EU, US and MENA on strategic, acquisition, and organisational issues. He has extensive experience in strategy implementation, integrating acquisitions, performance improvement and a range of finance functions including treasury and risk management. Prior to McKinsey Pat qualified as a Chartered Accountant with the audit and tax practice of Arthur Andersen. He has a first class honours degree in Commerce and a postgraduate diploma in Accounting and Corporate Finance from University College Dublin.
Dr Pamela Kirby
Independent non-executive director
Dr Kirby was CEO of Quintiles Transnational Corp and has held senior executive positions in F Hoffmann-La Roche Ltd and AstraZeneca plc. She has chaired Oxford Immunotec Ltd, was senior independent director of Informa plc and has previously held non-executive director positions with Smith & Nephew plc, Novo Nordisk A/S, Curalogic A/S and Oscient Pharmaceuticals Corp. Dr Kirby is chairman of Scynexis Inc and a non-executive director of DCC plc and Victrex plc. Dr Kirby holds a first-class Bachelor of Science degree in Pharmacology and a PhD in Clinical Pharmacology from the University of London.